STAT6 and neoplasm: Given that in three FL patients activating STAT6 (i.e. p.D419G, p.D419N, and p.D523V) mutations present in tumor tissue DNA were detectable in plasma cfDNA, it is possible to apply therapies targeting the JAK-STAT6 pathway for the FL patients with these mutations in cfDNA.